Company intelligence / Profile preview

ATTMOS

United States

Ownership: Private
Development stage: Other

Overview

ATTMOS develops and commercializes advanced, cloud-deployable computational chemistry platforms for drug discovery, enabling rapid identification of small molecule hits against challenging (often considered undruggable) oncology targets through physics-based simulations such as ABFEP, partnering with leading biotechs to advance preclinical programs.[2][3][9]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

IDEAYA Biosciences[2][3]

Beyond the preview

Go deeper on ATTMOS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATTMOS.

Explore the full profile